Contracts › 75N95022F00003
75N95022F00003: Management of Unhealthy Opioid and Polysubstance Use Among Patients in Primary Care Settings. FY22. Pop 9/15/22 - 9/14/27.
Awarded to The Emmes Company, Llc by National Institutes of Health (NIH).
$1.3Mobligated
$1.3Mpotential value
14 September 2027current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | 75N95022F00003 |
|---|---|
| Vehicle | 75N95020D00012 |
| Awardee | The Emmes Company, Llc |
| Awarding agency | National Institutes of Health (NIH) |
| Awarding office | NATIONAL INSTITUTES OF HEALTH NIDA |
| NAICS | 541715 Research and Development in the Physical, Engineering, and Life Sciences (Except Nanotechnology and Biotechnology) |
| PSC | AN11 Health R&D Services; Health Care Services; Basic Research |
| Place of performance | MD |
| Period of performance | 15 September 2022 to 14 September 2027 |
| Potential end | 14 September 2027 |
| Estimated recompete solicitation | ~Q1 2027 (estimate, ~6 months before expiry) |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 06 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541715 contracts · All expiring contracts · USASpending record